Galectin Therapeutics (GALT) ( (GALT) ) has released its Q2 earnings. Here is a breakdown of the information Galectin Therapeutics (GALT) presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for fibrotic disease and cancer using galectin science. In its latest earnings report for the quarter ended June 30, 2025, the company reported a net loss of $7.5 million, a decrease from the $12.4 million loss in the same period last year. Operating expenses were significantly reduced, with research and development expenses dropping to $3.3 million from $9.8 million a year ago. Despite the reduction in expenses, the company continues to operate at a loss, with no revenue generated. The company’s cash and cash equivalents stood at $13.8 million, down from $15.1 million at the end of 2024. Galectin Therapeutics has secured a new $10 million line of credit to support its operations through June 2026. Looking ahead, the company plans to raise additional capital through various strategic transactions to support its ongoing research and development efforts.